Jefferies on Corbus Pharmaceuticals (CRBP): FDA alignment de-risks, focus shifts to efficacy
Tweet Send to a Friend
Jefferies analyst Maury Raycroft reiterated a Buy rating and $36.00 price target on Corbus Pharmaceuticals (NASDAQ: CRBP)The analyst commented, "CRBP’s ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
